Sign In
Buy IGC
$0.268
+0.0079 (+3.04%)
At Close: Jul 20, 2026
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
08:30am, Monday, 25'th Nov 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment.
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
08:30am, Thursday, 14'th Nov 2024
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quar
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies
08:30am, Wednesday, 06'th Nov 2024
POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now a
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
08:30am, Thursday, 17'th Oct 2024
- Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Ba
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
09:00am, Thursday, 03'rd Oct 2024
POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer
Nokia deploys high-performance cross-border DWDM network for IGC
11:00pm, Sunday, 22'nd Sep 2024
Nokia's Dense Wavelength Division Multiplexing (DWDM) solution was used by IGC to overlay and enhance the existing infrastructure to more effectively manage the growing capacity demand.
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
08:00am, Wednesday, 18'th Sep 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment.
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
08:00am, Wednesday, 04'th Sep 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease.
IGC Pharma Reports First Quarter Fiscal 2025 Results
09:30pm, Thursday, 08'th Aug 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports First Quarter Fiscal 2025 Results.
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
09:10am, Tuesday, 09'th Jul 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
09:00am, Tuesday, 25'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
07:30pm, Monday, 24'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for Fiscal Year Ended March 31, 2024.
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
09:00am, Tuesday, 18'th Jun 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
09:00am, Tuesday, 28'th May 2024
POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.
